Is Syndax Pharmaceuticals, Inc. (SNDX)’s Fuel For Real? The Stock Just Increased Again

March 17, 2018 - By Adrian Erickson

The stock of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is a huge mover today! The stock increased 10.26% or $1.28 during the last trading session, reaching $13.76. About 762,170 shares traded or 92.26% up from the average. Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) has risen 7.09% since March 18, 2017 and is uptrending. It has underperformed by 9.61% the S&P500.
The move comes after 9 months positive chart setup for the $335.61M company. It was reported on Mar, 18 by We have $14.86 PT which if reached, will make NASDAQ:SNDX worth $26.85M more.

Analysts await Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) to report earnings on May, 14. They expect $-0.94 earnings per share, down 32.39 % or $0.23 from last year’s $-0.71 per share. After $-0.80 actual earnings per share reported by Syndax Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 17.50 % negative EPS growth.

Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The company has market cap of $335.61 million. The companyÂ’s lead product candidate is Entinostat, which is in Phase III clinical trial for the treatment of hormone receptor positive, human epidermal growth factor receptor 2 negative, and breast cancer; and Phase 2b clinical trial. It currently has negative earnings. It also develops SNDX-6352, an immunoglobulin G subclass 4 isotype that binds to the ligand binding domain of CSF-1R, blocking the binding and consequent activation by natural ligands interleukin-34 and colony stimulating factor-1, and disrupting tumor-associated macrophages activity.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.